Erudio Healtherudio.com
Sponsor
SOLTI Breast Cancer Research Group trials: what clinicians said in public
An HCP commentary report on 1 clinical trial sponsored by SOLTI Breast Cancer Research Group: RIBOLARIS. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 2 more trials with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (SOLTI Breast Cancer Research Group). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| RIBOLARIS NCT05296746 · SOLTI Breast Cancer Research Group | clinically high-risk ER+/HER2- stage II breast cancer | Phase 2 | 139 | 31 | Focused | Oct 30, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| PROMETEO NCT03802604 · SOLTI Breast Cancer Research Group StandardView → | residual HER2-negative breast cancer after neoadjuvant chemotherapy | Early phase 1 | Standard | View | |||
| TATEN NCT04251169 · SOLTI Breast Cancer Research Group FocusedView → | HR+/HER2- non-luminal metastatic breast cancer after CDK4/6 progression | Phase 2 | Focused | View | |||